The combination of BRAF ± MEK inhibitors with anti-EGFR monoclonal antibodies has achieved promising responses in this highly aggressive subset of colorectal cancer patients leading to improvement in survival and quality of life outcomes [21]. This evidence concerns the gene BRAF and colorectal cancer.